HUE062511T2 - Alzheimer-kór kezelése egy adott betegpopulációban - Google Patents

Alzheimer-kór kezelése egy adott betegpopulációban

Info

Publication number
HUE062511T2
HUE062511T2 HUE16845181A HUE16845181A HUE062511T2 HU E062511 T2 HUE062511 T2 HU E062511T2 HU E16845181 A HUE16845181 A HU E16845181A HU E16845181 A HUE16845181 A HU E16845181A HU E062511 T2 HUE062511 T2 HU E062511T2
Authority
HU
Hungary
Prior art keywords
alzheimer
disease
treatment
patient population
specific patient
Prior art date
Application number
HUE16845181A
Other languages
English (en)
Hungarian (hu)
Inventor
Susan Abushakra
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE062511(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of HUE062511T2 publication Critical patent/HUE062511T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE16845181A 2015-09-10 2016-09-09 Alzheimer-kór kezelése egy adott betegpopulációban HUE062511T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
HUE062511T2 true HUE062511T2 (hu) 2023-11-28

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16845181A HUE062511T2 (hu) 2015-09-10 2016-09-09 Alzheimer-kór kezelése egy adott betegpopulációban

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP4275750A3 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102412997B1 (enExample)
CN (3) CN108289870A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015230972B2 (en) 2014-03-21 2021-05-27 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
CN114805211B (zh) 2017-03-21 2024-08-23 润佳(苏州)医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
PL3829568T3 (pl) * 2018-08-01 2024-03-25 Alzheon, Inc. Pochodne kwasu sulfopropanowego do leczenia zaburzeń neurodegeneracyjnych
LT3829563T (lt) * 2018-08-01 2025-02-25 Alzheon, Inc. 3-sulfopropano rūgštis neurodegeneracinėms ligoms gydyti
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CN114269949A (zh) 2019-06-17 2022-04-01 阿尔泽恩股份有限公司 用于治疗神经变性病症的方法
CN112791078B (zh) 2019-11-13 2022-12-06 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.
US20250127734A1 (en) * 2022-02-07 2025-04-24 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1994009155A1 (en) 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
WO2005060393A2 (en) 2003-08-11 2005-07-07 California Institute Of Technology Microfluidic large scale integration
JP2008535907A (ja) * 2005-04-12 2008-09-04 ニユーロケム(インターナショナル)、リミテッド アミロイド阻害化合物の薬学的製剤
EP2862581B1 (en) 2006-10-12 2021-08-11 BHI Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US20100183513A1 (en) 2006-11-24 2010-07-22 Wolfgang Froestl N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
DK2605655T3 (en) * 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
JP6424210B2 (ja) * 2013-05-06 2018-11-14 バクスアルタ インコーポレイテッド プールされた免疫グロブリンgを用いたアルツハイマー病の亜集団の治療
BR112016018170A2 (pt) 2014-02-08 2018-02-20 Genentech, Inc. métodos para tratar doença de alzheimer
AU2015230972B2 (en) 2014-03-21 2021-05-27 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population

Also Published As

Publication number Publication date
WO2017044840A1 (en) 2017-03-16
SMT202300250T1 (it) 2023-09-06
MD3347002T2 (ro) 2023-10-31
HK1257874A1 (en) 2019-11-01
CA2997376C (en) 2024-05-14
MX2018003023A (es) 2018-06-06
KR20180051561A (ko) 2018-05-16
DK3347002T3 (da) 2023-08-14
US20230414541A1 (en) 2023-12-28
PL3347002T3 (pl) 2023-11-13
RS64481B1 (sr) 2023-09-29
FI3347002T3 (fi) 2023-08-10
US11191742B2 (en) 2021-12-07
CN108289870A (zh) 2018-07-17
JP2022145949A (ja) 2022-10-04
LT3347002T (lt) 2023-09-11
US20220096406A1 (en) 2022-03-31
CN116712422A (zh) 2023-09-08
MX2022003128A (es) 2022-08-02
EP3347002B1 (en) 2023-06-07
JP2025065545A (ja) 2025-04-17
AU2016319107A1 (en) 2018-03-22
KR102412997B1 (ko) 2022-06-23
KR20220042480A (ko) 2022-04-05
AU2016319107B2 (en) 2021-02-25
KR102547164B1 (ko) 2023-06-22
EP4275750A3 (en) 2024-01-17
JP2018526407A (ja) 2018-09-13
CA2997376A1 (en) 2017-03-16
JP6789579B2 (ja) 2020-11-25
HRP20230809T1 (hr) 2023-10-27
EP3347002A4 (en) 2019-04-24
PT3347002T (pt) 2023-07-27
JP2020200352A (ja) 2020-12-17
EP4275750A2 (en) 2023-11-15
SI3347002T1 (sl) 2023-12-29
EP3347002A1 (en) 2018-07-18
CN116712423A (zh) 2023-09-08
MX392677B (es) 2025-03-24
ES2952727T3 (es) 2023-11-03
JP7128536B2 (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
HUE062511T2 (hu) Alzheimer-kór kezelése egy adott betegpopulációban
CY2023010I2 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
MA45192A (fr) Traitement d'association
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
IL247085B (en) Methods for treating Alzheimer's disease
HUE063369T2 (hu) Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
IL246999B (en) Methods for treating Alzheimer's disease
DK3294345T3 (da) Tpp1-formuleringer og fremgangsmåder til behandling af cln2-sygdom
IL263433A (en) Methods for treating alzheimer's disease
HUE059387T2 (hu) Parkinson-kór kezelése
DK3244920T3 (da) Mund- og klovsyge-vaccine
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
EP3338730A4 (en) ORTHODONTIC IMPLANT STRUCTURE AND ORTHODONTIC IMPLANT DEVICE
HUE069280T2 (hu) Ebselen a Meniere-kór kezelésére történõ felhasználásra
EP3137097C0 (en) TREATMENT AND PREVENTION OF ALZHEIMER
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
DK3137094T3 (da) Behandling og forebyggelse af alzheimers sygdom (ad)
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
PL3137093T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
EP3322481A4 (en) TREATMENT OF ROTATOR COIL DRESSES
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
DK3072509T3 (da) Sammensætninger til behandling af mortellaros sygdom og fremgangsmåder til fremstilling deraf
GB201511453D0 (en) Treatment of alzheimer's disease